Literature DB >> 18444974

The use of glucan as immunostimulant in the treatment of a severe case of chromoblastomycosis.

Conceição de Maria Pedrozo e Silva Azevedo, Sirley Garcia Marques, Maria Aparecida Resende, Azizedite Guedes Gonçalves, Daniel Vagner de Castro Lima Santos, Raimunda Ribeiro da Silva, Maria da Glória Teixeira de Sousa, Sandro Rogerio de Almeida.   

Abstract

We report the case of an alternative treatment for a patient with a severe form of chromoblastomycosis that responded poorly to the traditional antifungal therapy. We hereby show, in this study, the improvement of lesions after treatment with itraconazole associated with an intramuscular administration of glucan. We observed that the regression of lesions was associated with an improvement of the cellular immune response. This favourable response that we observed suggests that the therapeutic regimen we used might be an option for the treatment of patients with a severe form of chromoblastomycosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18444974     DOI: 10.1111/j.1439-0507.2007.01485.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  8 in total

Review 1.  Chromoblastomycosis.

Authors:  Flavio Queiroz-Telles; Sybren de Hoog; Daniel Wagner C L Santos; Claudio Guedes Salgado; Vania Aparecida Vicente; Alexandro Bonifaz; Emmanuel Roilides; Liyan Xi; Conceição de Maria Pedrozo E Silva Azevedo; Moises Batista da Silva; Zoe Dorothea Pana; Arnaldo Lopes Colombo; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 2.  Challenges in the therapy of chromoblastomycosis.

Authors:  Flavio Queiroz-Telles; Daniel Wagner de C L Santos
Journal:  Mycopathologia       Date:  2013-05-02       Impact factor: 2.574

3.  Potentiation of Innate Immunity by β-Glucans.

Authors:  Su Kyoung Seong; Ha Won Kim
Journal:  Mycobiology       Date:  2010-06-30       Impact factor: 1.858

Review 4.  Chromoblastomycosis: an etiological, epidemiological, clinical, diagnostic, and treatment update.

Authors:  Arival Cardoso de Brito; Maraya de Jesus Semblano Bittencourt
Journal:  An Bras Dermatol       Date:  2018 Jul-Aug       Impact factor: 1.896

Review 5.  Immune Sensing and Potential Immunotherapeutic Approaches to Control Chromoblastomycosis.

Authors:  Leandro C D Breda; Isabela G Menezes; Larissa N M Paulo; Sandro Rogério de Almeida
Journal:  J Fungi (Basel)       Date:  2020-12-22

Review 6.  Reviewing the Etiologic Agents, Microbe-Host Relationship, Immune Response, Diagnosis, and Treatment in Chromoblastomycosis.

Authors:  Luiz Felipe Domingues Passero; Italo Novais Cavallone; Walter Belda
Journal:  J Immunol Res       Date:  2021-11-01       Impact factor: 4.818

7.  Combination therapy for an elderly patient with chromoblastomycosis caused by Fonsecaea monophora: a case report.

Authors:  Yu Shen; Boxuan Jiang; Han Zhang; Jinrong Feng; Hui Hua
Journal:  Ann Transl Med       Date:  2022-01

8.  A Case of Chromoblastomycosis Caused by Fonsecaea pedrosoi Successfully Treated by Oral Itraconazole Together with Terbinafine.

Authors:  Xu-Cheng Shen; Xiang-Nong Dai; Zhi-Min Xie; Ping Li; Sha Lu; Jia-Hao Li; Yi Zhang; Xing-Dong Ye
Journal:  Dermatol Ther (Heidelb)       Date:  2020-02-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.